← Leaderboards
Frederick Albert Schroeder
Eikonizo Therapeutics, Inc.
$809,672
Attributed
$809,672
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$809,672 · 2
By mechanism
R43$809,672 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposHdac6 GeneEnzymesPositron-Emission TomographyMolecularImaging AgentIn VivoInhibitor/AntagonistLeadPharmaceutical PreparationsSignal TransductionMouse ModelBaseProteinsBrainDrug CandidateAnalogAmyloid Beta-ProteinAge-MonthsAmyloidBiotechnologyAmericanAffectAdrenergic Agents
Grant awards (2)
Mechanistic Validation of Selective Brain-Penetrant HDAC6 Inhibitors as a Disease- Modifying Treatment for Tauopathies including Alzheimer's Disease$509,672
R43 · FY2020 · AG · contact PI
Targeting HDAC6 to Modulate Titin Stiffness for Dilated Cardiomyopathy Therapy$300,000
R43 · FY2020 · HL · contact PI